AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03583385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucophage XR (Test drug)
Description: Participants received single oral dose of Glucophage® XR tablet manufactured by PT Merck Tbk, Jakarta, Indonesia (Test Drug) under fasted conditions.
Study NCT03583385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucophage XR (Comparator drug)
Description: Participants received single oral dose of Glucophage® XR tablet manufactured by Merck Santé, Semoy, France (Comparator Drug) under fasted conditions.
Study NCT03690752 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: unweighting using Alter-G Anti-Gravity Treadmill
Description: The unweighted group (experimental) is allowed to self-select a comfortable unweighting using the weight control feature on the Alter-G Anti-Gravity Treadmill. Both groups use the same Alter-G Anti-Gravity Treadmill and both groups are about to self-select speed, incline, and duration.
Study NCT03690752 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: normal weight using Alter-G Anti-Gravity Treadmill
Description: The weighted (control) group will walk at 100% their body weight using the Alter-G Anti-Gravity Treadmill. Both groups use the same Alter-G Anti-Gravity Treadmill and both groups are about to self-select speed, incline, and duration.
Study NCT03261427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lyrica 150Mg Capsule
Description: 150 mg oral administered (BID)
Study NCT03261427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YNP-1807 330Mg Tablet
Description: 330 mg oral administered (QD)
Study NCT02935439 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cell Phone
Description: Participants responded to questions about their heart failure symptoms using a cell phone.
Study NCT03577730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine Citrate
Description: Prepared intravenous piggyback solutions of caffeine citrate (200 mg caffeine) will be directly delivered to the operating room prior to the surgery of enrolled participants.
Study NCT01330108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ambrisentan
Description: ambrisentan 2.5mg, 5mg, \& 10mg. Daily dosage.
Study NCT03577730 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextrose Water
Description: Prepared intravenous piggyback solutions of 5 percent dextrose water will be directly delivered to the operating room prior to the surgery of enrolled participants.
Study NCT01160302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microgranular Curcumin C3 Complex®
Description: 4 grams twice daily for 21-28 days
Study NCT00953433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoflex tube
Description: Size decided upon gender.
Study NCT00953433 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polyvinyl chloride endotracheal tube with a stylet
Description: Size decided upon gender.
Study NCT00917696 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Iontophoresis and Laser Doppler with ATP
Description: Iontophoresis treatments with 10 mM ATP (adenosine triphosphate) solution and a current of 0.8 or 1.2 mA. Iontophoresis treatments will last 4 minutes. Laser doppler will be used during the iontophoresis treatments to measure dermal blood flow.
Study NCT00917696 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Iontophoresis and Laser Doppler with Saline
Description: Iontophoresis treatments with 20 mM saline solution and a current of 0.8 or 1.2 mA. Iontophoresis treatments will last 4 minutes. Laser doppler will be used during the iontophoresis treatments to measure dermal blood flow.
Study NCT03815513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: brain MRI
Description: both case and control groups received brain MRI to evaluate cerebrovascular reactivity
Study NCT02437708 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: REP with L-PRF
Study NCT02598310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab-paclitaxel 260mg/m2 q3w
Study NCT02598310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: trastuzumab 6 mg/kg (8 mg/kg as the loading dose)
Study NCT02508792 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LASER
Description: Low level LASER therapy will be applied in six different regions of the thight from the dominant limb, before a fatigue protocol using a isokinetic equipment.
Study NCT00636766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
Study NCT02437708 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: REP
Study NCT02508792 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: LASER PLACEBO
Description: The low level LASER therapy turned off (placebo) will be applied in six different regions of the thight from the dominant limb, before a fatigue protocol using a isokinetic equipment.
Study NCT02437708 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: stem and progenitor cells
Study NCT03578952 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAVR with Evolut R valve
Description: TAVR with Evolut R valve
Study NCT03445169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belzutifan
Description: Belzutifan Tablets
Study NCT02975596 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Awareness
Description: Awareness: Conduct an awareness campaign throughout Alachua County to alert the community in general to the significance of Serogroup B meningococcal disease in the United States. To inform the material included in the awareness campaign and the education materials, semi-structured interviews with members for each of the key stakeholder groups: students, parents, and medical practitioners will be conducted.
Study NCT00636766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rimonabant
Description: A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
Study NCT00636766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Description: A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
Study NCT02975596 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Education
Description: Education: This component will be both web-based and in-person to meet the individual needs of the learners. There will be parent and a student (18-23 years old) version of the educational curriculum. National resources of patient -focused materials and guidelines will be adapted. There will be pre- and post-education surveys to assess knowledge and vaccine decision-making.
Study NCT00636766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
Study NCT00928551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vabicaserin
Study NCT02089399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevikar(amlodipne/olmesartan)
Description: Treatment AB
Study NCT02089399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crestor(Rosuvastatin)
Description: Treatment AB/Treatment C
Study NCT02690870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: Patients in the tamoxifen group will take 20 mg of tamoxifen oral tablets daily from day 3 of the menses for 5 days.
Study NCT02690870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene
Description: Patients in clomiphene group will take 100 mg of CC oral tablets daily from day 3 of the menses for 5 days.
Study NCT01585506 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: Patients to complete the WHO-5 Well-being Index questionnaire
Study NCT02975596 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Empowerment
Description: Empowerment: A guided program for adolescents and young adults on Decision-Making for your Health will be offered on the vaccination days to assist youth in assessing and utilizing health information to guide their personal decision-making for vaccines.
Study NCT02975596 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Accessibility
Description: Accessibility: MenB vaccine will be offer on the high school and university campuses through a collaborative program between the local schools, university and department of health. We will offer students booster shots of Men ACWY and HPV at the same time. All vaccines will be offered free of charge. Each vaccine administered will be recorded in Florida SHOTS.
Study NCT01585506 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: Physicians to complete two questionnaires, Demographic Data and Disease and Treatment Course and Questionnaire of Potential Difficulties in the Period of Treatment Switching from Insulin to Its Analogues
Study NCT00194532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefpodoxime
Description: Cefpodoxime 100mg twice a day(BID)for 3 days
Study NCT00194532 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Ciprofloxacin 250mg twice a day (BID)for 3 days
Study NCT02934503 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg IV fixed dose every 3 weeks until progression or for up to 2 years of therapy.
Study NCT02934503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2
Study NCT02934503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6
Study NCT02934503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: IV every 3 weeks for up to 6 cycles (minimum of 4 cycles, maximum of 6).
Study NCT00272402 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Intervention
Description: Intervention consists of simulated case based learning for physicians.
Study NCT00272402 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Office System Redesign Intervention
Description: Intervention consists of clinical decision support within the electronic medical record.
Study NCT02934503 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Thoracic radiotherapy will be given per institutional standards(dose and duration may vary for individual participants).
Study NCT01669239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Doxorubicin
Description: Six cycles of:~* Trastuzumab 4 mg/kg loading dose on Day 1 of the first cycle, then 2 mg/kg on Days 8 and 15 of the first cycle and on Days 1, 8, and 15 of the subsequent cycles, every 3 weeks~* Pertuzumab 840 mg loading dose on Day 1 of the first cycle, then 420 mg on Day 1, every 3 weeks~* Liposomal doxorubicin 50 mg/m2 on Day 1, every 3 weeks~* Paclitaxel 80 mg/m2 on Days 1, 8, and 15, every 3 weeks
Study NCT03851289 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: platelet-rich fibrin and calcium sulfate
Study NCT03851289 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: platelet-rich fibrin and xenograft
Study NCT04252729 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Psychotherapy sessions based on Psychoanalytic Psychosomatics
Study NCT06064448 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Subjects were given sildenafil citrate, 25mg/capsule, once a night, one capsule each time, for 4 weeks.
Study NCT00925015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dalotuzumab 10 mg/kg
Description: Dalotuzumab at 10 mg/kg was intravenously administered once weekly
Study NCT02054104 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H1299 cell lysates
Description: H1299 cell lysate with iscomatrix adjuvant vaccine via subcutaneous injections once every cycle (cycle=28 days) for 6 cycles total. Additional 2 injections for patients with immunologic response and no clinical evidence of active disease (NED).
Study NCT06064448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ningmitai capsule
Description: The subjects took Ningmitai capsule, 0.38 g/capsule, 3 times a day, 4 capsules each time, after meals, and continued to treat for 4 weeks.
Study NCT06064448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ningbitai capsule + sildenafil
Description: The subjects took Ningmitai capsule orally, 0.38 g/capsule, 3 times a day, 4 capsules each time, and took it after meals. Sildenafil citrate, 25mg/capsule, once a night, one capsule each time, was taken orally for 4 weeks.
Study NCT00925015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Following pre-treatment with a histamine-receptor antagonist, Cetuximab was administered with an initial intravenous infusion of 400 mg/m\^2, followed by subsequent once weekly intravenous infusions of 250 mg/m\^2
Study NCT00925015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan was administered with an intravenous infusion of 150 mg/m\^2, once every other week for 42 days
Study NCT00925015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dalotuzumab 15/7.5 mg/kg
Description: Dalotuzumab was intravenously administered, with the first infusion of 15 mg/kg, followed by subsequent infusions of 7.5 mg/kg
Study NCT02054104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg by mouth (PO) twice a day (BID) for 7 days prior to the first dose of vaccine and then on days 8 through 14, and 22 through 28 of each treatment cycle.
Study NCT02054104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 400 mg by mouth (PO) twice a day (BID) for 7 days prior to the first dose of vaccine and then on days 1 through 28 of each treatment cycle.
Study NCT02054104 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Iscomatrix adjuvant
Description: H1299 cell lysate with iscomatrix adjuvant vaccine via subcutaneous injections once every cycle (cycle=28 days) for 6 cycles total. Additional 2 injections for patients with immunologic response and no clinical evidence of active disease (NED).
Study NCT00975156 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Conventional physical therapy
Study NCT00975156 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat
Description: Robotic-assisted walking device
Study NCT02375230 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Health care provider randomized to the control group will receive a copy of the NRP text pages discussing MR SOPA at every shift for self-study. They will be encouraged by the educator to study these pages for five minutes at every shift. The educator will be there to answer questions if they arise.
Study NCT02375230 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MR SOPA
Description: Health care provider randomized to the MR SOPA group will receive MR SOPA training provided by a qualified educator on every shift. This training will be five minutes long and will consist of each MR SOPA step. These corrective steps will be demonstrated and practiced on a low-fidelity neonatal mannequin. The alternative airway practice will be performed on an intubation mannequin in the DR also placed on the DR resuscitation unit. Each participant will receive five minutes of training at the start of each shift.
Study NCT03548181 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Autonomous Physiotherapist Agent (VAPA)
Description: A Virtual Autonomous Physiotherapist Agent is going to gide and motivate the patient to train physically at home.
Study NCT00933075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LACTIC ACID(ND)
Description: Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative for 5 weeks (treatment period).
Study NCT02531581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: furosemide 40 mg bolus with second bolus to 4 hours so inadequate diuretic response defined as urine output \<500cc
Study NCT02531581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaCl 9% isotonic
Description: normal saline 500 cc / 4 hours and 1 L / 24 hours
Study NCT03958227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manuel Therapy plus Exercise Intervention
Description: Shoulder mobilization techniques include glenohumeral traction, anterior, posterior and inferior glide. We will also use anterior, posterior and inferior joint stretching exercises and scapular mobilization. Exercise interventions include range of motion exercises, stretching exercises, strengthening exercises, and pendulum exercises.
Study NCT03958227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Exercise interventions include range of motion exercises, stretching exercises, strengthening exercises, and pendulum exercises.
Study NCT04546477 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Stent implantation
Description: Procedure can be conducted via either contralateral or antegrade approach. After a successful target lesion crossing, predilate the lesion using either plain old balloon angioplasty (POBA) or (if necessary) any available specialty balloon. The inflated diameter of the balloon should approximate the diameter of the vessel just distal to the lesion. Proper vessel preparation should achieve diameter of 1:1 to healthy vessel (with ≤20% residual stenosis, as per operator's assessment). Adjunctive debulking devices are prohibited.~Final stent selection should be confirmed after a proper vessel preparation, considering the reference vessel diameter (RVD) for the optimal 1:1 stent-to-vessel sizing. The implanted dual layer length would encompass the entire lesion with the micromesh, covering it from healthy to healthy tissue. Post-dilatation of the stent for more optimal placement may be done at operator's discretion, using standard angioplasty with uncoated balloon.
Study NCT01972048 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mMammogram
Description: Text messages delivered via mobile app to participants designed to inform them about breast cancer screening and encourage them to schedule a mammogram.
Study NCT01972048 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Print brochure
Description: Mailed print brochure about breast cancer screening and community resources.
Study NCT00475683 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Mouth wash
Description: Mouth wash with chlorehexidin, three times a day
Study NCT00475683 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumol
Description: 5 ml in 50 ml water, mouthwash for 30 seconds, three times a day
Study NCT03548181 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Autonomous Physiotherapist Agent (VAPA)
Description: A Virtual Autonomous Physiotherapist Agent is going to gide and motivate the patient to train physically at home.
Study NCT03725878 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard tertiary interventions of birth defects
Description: Couples eligible for reproductive policy are entitled to routine health cares including general health cares (health education, medical history inquiry, physical examinations, consulting guidance and pregnancy outcome follow-up) and medical examinations (laboratory examinations, virus screenings and image examinations). But nutrients status are not included in these examinations, such as folate, vitamin B12, and macroelements, et al. Regular antenatal cares are required, such as deformity screening by ultrasound. Routine neonatal screenings are conducted to diagnose infant with birth defect timely.